Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Newbury Pharmaceuticals

1.94 SEK-3.73 %19.11, 17.29
Less than 1K followers

NEWBRY

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-3.73 %
-4.68 %
-18.35 %
+42.28 %
+68.26 %
+24.84 %
-47.98 %
-
-84.64 %

Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.

Read more
Market cap
58.82M SEK
Turnover
28.01K SEK
Revenue
42.69M
EBIT %
-48.4 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.1
2027

General meeting '27

20.1
2027

Interim report Q1'27

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release18.11.2026, 18.25

Newbury Pharmaceuticals extends and increases loan agreement to SEK 40m, with right to early repayment

Newbury Pharmaceuticals
Press release17.11.2026, 09.00

Newbury Pharmaceuticals’ international business receives orders worth approximately SEK 14.5 million

Newbury Pharmaceuticals
Press release10.11.2026, 09.00

Newbury Pharmaceuticals Wins Two Swedish Hospital Tenders for Irinotecan Amarox

Newbury Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release28.10.2026, 08.00

Newbury Pharmaceuticals year-end report September 2025 – August 2026

Newbury Pharmaceuticals
Press release27.10.2026, 17.00

Newbury Pharmaceuticals Secures Generic Approval for Prukalopride Newbury

Newbury Pharmaceuticals
Press release26.10.2026, 10.00

Newbury Pharmaceuticals international receives import approvals for 19 hospital product

Newbury Pharmaceuticals
Press release28.09.2026, 14.00

Newbury Pharmaceuticals secures exclusive rights to a 40-product hospital portfolio in Iraq

Newbury Pharmaceuticals
Press release17.08.2026, 15.15

Newbury Pharmaceuticals accelerates its neuroscience ambitions with a new partnership for Guanfacine tablets

Newbury Pharmaceuticals
Press release13.07.2026, 09.00

Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury

Newbury Pharmaceuticals
Press release10.07.2026, 14.45

Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury

Newbury Pharmaceuticals
Regulatory press release08.07.2026, 08.00

Newbury Pharmaceuticals interim report September 2025 – May 2026

Newbury Pharmaceuticals
Press release17.04.2026, 10.00

Newbury Pharmaceuticals Secures Generic Approval for Palbociclib Newbury

Newbury Pharmaceuticals
Regulatory press release15.04.2026, 10.30

Extraordinary General Meeting of Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Regulatory press release15.04.2026, 08.00

Newbury Pharmaceuticals interim report September 2025 – February 2026

Newbury Pharmaceuticals
Regulatory press release26.03.2026, 19.30

Kallelse till extra bolagsstämma i Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Regulatory press release26.03.2026, 14.00

Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM

Newbury Pharmaceuticals
Press release18.03.2026, 16.45

Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets

Newbury Pharmaceuticals
Press release29.01.2026, 12.00

Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark

Newbury Pharmaceuticals
Regulatory press release21.01.2026, 08.00

Newbury Pharmaceuticals interim report September 2025 – November 2025

Newbury Pharmaceuticals
Regulatory press release14.01.2026, 11.15

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

Newbury Pharmaceuticals